Table of Contents
Advertisement
Acessa
ProVu System User's Guide
®
Percent Change From Baseline in Total Uterine and Fibroid Volume at 3 and 12 Months Post treatment Based on
UFS-QOL Scores
13.11.
Mean Health-Related Quality of Life (HRQL) scores and Symptom Severity Scores (SSS) improved significantly from
baseline to 3 months, then remained similar at all intervals between 3 and 36 months post treatment.
UFS-QOL Symptom Severity and HRQL Scores at Baseline and at 3, 6, 12, 24, and 36 Months Post Treatment
90
80
70
60
50
40
30
20
10
0
Baseline
(n=127)
UFS-QOL Concern, Activities, Energy/Mood, Control, Self-Consciousness, and Sexual Function Scores at 3, 6, 12, 24, and
100
90
80
70
60
67
50
40
30
20
25
10
0
Concern
CO 20-131 Revision: C
Preoperative and Postoperative MRI Assessments
Month 3
0%
-10%
-20%
-16%
-30%
-40%
-38%
-50%
-60%
75
61
37
29
Month 3
Month 6
(n=124)
(n=125)
36 Months Post Treatment
81
80
79
77
77
71
71
69
68
37
Activities
Baseline
Month 3
(n=127)
(n=124)
Month 12
-25%
-44%
80
78
29
27
Month 12
Month 24
(n=124)
(n=112)
86
84
81
80
79
79
76
75
45
38
Energy
Control
Month 6
Month 12
(n=125)
(n=124)
PL-01-0040
Uterine Volume
Fibroid Volume
79
76
29
25
Month 36
(n=107)
86
83
82
80
78
77
75
45
38
Self-Conscious
Sexual Function
Month 24
Month 36
(n=112)
(n=107)
Symptom
Severity
HRQL
79
75
75
74
74
26
Advertisement
Table of Contents
